This inventor holds 1 USPTO granted patent. Top assignee: Wntrx Pharmaceuticals Inc.. Active years: 2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2023
Title: Yvonne Angell: Innovator in Biopharmaceuticals
Introduction
Yvonne Angell is a prominent inventor based in San Francisco, CA. She has made significant contributions to the field of biopharmaceuticals, particularly through her innovative work on polypeptides derived from the BCL9 protein.
Latest Patents
Yvonne Angell holds 1 patent for her invention related to BCL9 peptides and variants thereof. This patent discloses polypeptides derived from the HD2 domain of the human B-cell CLL/lymphoma 9 (BCL9) protein. The invention outlines their use in the diagnosis, prevention, and treatment of various diseases and disorders. Additionally, it includes methods for generating such polypeptides and their variants.
Career Highlights
Yvonne Angell has established herself as a key figure in her field, working at Wntrx Pharmaceuticals Inc. Her expertise in biopharmaceuticals has positioned her as a valuable asset in the development of innovative therapeutic solutions.
Collaborations
Yvonne collaborates with notable colleagues, including Robert B. Perni and David Zhu. Their combined efforts contribute to advancing research and development in the biopharmaceutical sector.
Conclusion
Yvonne Angell's work exemplifies the impact of innovation in the biopharmaceutical industry. Her contributions through her patent on BCL9 peptides highlight the potential for new treatments and diagnostic methods.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile